A G-quartet oligonucleotide blocks glycoprotein Ib-mediated platelet adhesion and aggregation under flow conditions

Summary

Platelets arrest bleeding by adhering to and aggregating on the subendothelium exposed at the site of vessel injury.This process is initiated by the interaction between the subendothelium von Willebrand factor (VWF) and the glycoprotein (GP) Ib-IX-V complex on platelets.However,the same interaction also results in thrombosis at the site of a ruptured atherosclerotic plaque. Reagents regulating the GP Ib-VWF interaction will therefore have direct impact on haemostasis and thrombosis. We have characterised an oligonucleotide G-quartet (T30923) that specifically blocks VWF binding to GP Ibα, theVWF-binding subunit of the GP Ib-IX-V complex.We evaluated the potential interactions of T30923 with GP Ibα and VWF A1 domain by computer simulated molecular dockings, which identified four T30923 docking sites in the β-sheets of the N-terminal region of GP Ibα (E14-D18, S39, D63-S64, and D83-S85). Experimentally,T30923 bound GP Ibα and dose-dependently blocked platelet aggregation induced by ristocetin and thrombin, but not by botrocetin, collagen, TRAP, and ADP. It also blocked shear-induced platelet aggregation and thrombus formation on immobilized VWF under arterial shear stress. These results demonstrate that T30923 may have therapeutic potentials to regulate the GP IbαVWF interaction.

Keywords

Oligonucleotide - G-quartet - platelet - GP Ib - von Willebrand factor - shear stress

• References

• 1 Lopez JA. The platelet glycoprotein Ib-IX complex. Blood Coagul Fibrinolysis 1994; 05: 97-119.
• 2 Ware J. Molecular analyses of the platelet glycoprotein Ib-IX-V receptor. Thromb Haemost 1998; 79: 466-478.
• 3 Lopez JA, Andrews RK, Afshar-Kharghan V. et al. Bernard-Soulier syndrome. Blood 1998; 91: 4397-4418.
• 4 Furlan M. Von Willebrand factor: molecular size and functional activity. Ann Hematol 1996; 72: 341-348.
• 5 Shen Y, Romo GM, Dong JF. et al. Requirement of leucine-rich repeats of glycoprotein (GP) Ibalpha for shear-dependent and static binding of von Willebrand factor to the platelet membrane GP Ib-IX-V complex. Blood 2000; 95: 903-910.
• 6 Shen Y, Cranmer SL, Aprico A. et al. Leucine-rich repeats 2–4 (Leu60-Glu128) of platelet glycoprotein Ibalpha regulate shear-dependent cell adhesion to von Willebrand factor. J Biol Chem 2006; 281: 26419-26423.
• 7 Dong JF, Berndt MC, Schade A. et al. Ristocetindependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions. Blood 2001; 97: 162-168.
• 8 Peng Y, Berndt MC, Cruz MA. et al. The alpha1 helix-beta13 strand spanning Leu214 to Val229 of platelet glycoprotein Ibalpha facilitates the interaction with von Willebrand factor: evidence from characterization of the epitope of monoclonal antibody AP1. Blood 2004; 104: 3971-3978.
• 9 Huizinga EG, Tsuji S, Romijn RA. et al. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science 2002; 297: 1176-1179.
• 10 Dumas JJ, Kumar R, McDonagh T. et al. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations. J Biol Chem 2004; 279: 23327-23334.
• 11 Paborsky LR, McCurdy SN, Griffin LC. et al. The single-stranded DNA aptamer-binding site of human thrombin. J Biol Chem 1993; 268: 20808-20811.
• 12 Li WX, Kaplan AV, Grant GW. et al. A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation. Blood 1994; 83: 677-682.
• 13 Oney S, Nimjee SM, Layzer J. et al. Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides 2007; 17: 265-274.
• 14 Gilbert JC, DeFeo-Fraulini T, Hutabarat RM. et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007; 116: 2678-2686.
• 15 Williamson JR. G-quartet structures in telomeric DNA. Annu Rev Biophys Biomol Struct 1994; 23: 703-730.
• 16 Jing N, Marchand C, Liu J. et al. Mechanism of inhibition of HIV-1 integrase by G-tetrad-forming oligonucleotides in Vitro. J Biol Chem 2000; 275: 21460-21467.
• 17 Jing N, Rando RF, Pommier Y, Hogan ME. Ion selective folding of loop domains in a potent anti-HIV oligonucleotide. Biochemistry 1997; 36: 12498-12505.
• 18 Zhu Q, Jing N. Computational study on mechanism of G-quartet oligonucleotide T40214 selectively targeting Stat3. J Comput Aided Mol Des 2007; 21: 641-648.
• 19 Jing N, Gao X, Rando RF, Hogan ME. Potassiuminduced loop conformational transition of a potent anti HIV oligonucleotide. J Biomol Struct Dyn 1997; 15: 573-585.
• 20 Zhang JN, Bergeron AL, Yu Q. et al. Platelet Aggregation and Activation under Complex Patterns of Shear Stress. Thromb Haemost 2002; 88: 817-821.
• 21 Bernardo A, Bergeron AL, Sun CW. et al. Von Willebrand factor present in fibrillar collagen enhances platelet adhesion to collagen and collagen-induced platelet aggregation. J Thromb Haemost 2004; 02: 660-669.
• 22 Dong JF, Li CQ, Sae-Tung G. et al. The cytoplasmic domain of glycoprotein (GP) Ibalpha constrains the lateral diffusion of the GP Ib-IX complex and modulates von Willebrand factor binding. Biochemistry 1997; 36: 12421-12427.
• 23 Berndt MC, Shen Y, Dopheide SM. et al. The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost 2001; 86: 178-188.
• 24 Bishop JS, Guy-Caffey JK, Ojwang JO. et al. Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide. J Biol Chem 1996; 271: 5698-5703.
• 25 Jing N. Developing G-quartet oligonucleotides as novel anti-HIV agents: focus on anti-HIV drug design. Expert Opin Investig Drugs 2000; 09: 1777-1785.
• 26 Berndt MC, Ward CM, Booth WJ. et al. Identification of aspartic acid 514 through glutamic acid 542 as a glycoprotein Ib-IX complex receptor recognition sequence in von Willebrand factor. Mechanism of modulation of von Willebrand factor by ristocetin and botrocetin. Biochemistry 1992; 31: 11144-11151.
• 27 Vu TK, Hung DT, Wheaton VI. et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-1068.
• 28 Harmon JT, Jamieson GA. The glycocalicin portion of platelet glycoprotein Ib expresses both high and moderate affinity receptor sites for thrombin. A soluble radioreceptor assay for the interaction of thrombin with platelets. J Biol Chem 1986; 261: 13224-13229.
• 29 De Marco L, Mazzucato M, Masotti A. et al. Function of glycoprotein Ib alpha in platelet activation induced by alpha-thrombin. J Biol Chem 1991; 266: 23776-23783.
• 30 Ward CM, Andrews RK, Smith AI. et al. Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha-thrombin. Biochemistry 1996; 35: 4929-4938.
• 31 Marchese P, Murata M, Mazzucato M. et al. Identification of three tyrosine residues of glycoprotein Ib alpha with distinct roles in von Willebrand factor and alpha-thrombin binding. J Biol Chem 1995; 270: 9571-9578.
• 32 Celikel R, McClintock RA, Roberts JR. et al. Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ibalpha. Science 2003; 301: 218-221.